Philippine Trial to Determine Efficacy and Safety of Favipiravir for COVID-19

Inclusion Criteria:

- Age: 18 to 74 years (at the time of informed consent)

- Gender: Male or female

- Patients with SARS-CoV-2-positive nasopharyngeal swab by RT-PCR test with non-severe
presentation upon admission to clinical trial site hospitals or trial-supervised
quarantine facilities or under trial -supervised home isolation;

- For premenopausal female patients, patients who have been confirmed to be negative on
a pregnancy test before administration of the study drug;

- Patients who understand the contents of this study and can provide written consent by
themselves without assistance, or as appropriate with their assent and consent of
their parents

Exclusion Criteria:

- Patient has manifestation that meets case definition of Severe COVID-19: Adult with
clinical signs of pneumonia (fever, cough, dyspnea, fast breathing) plus one of the
following: respiratory rate > 30 breaths/min; severe respiratory distress; or SpO2 <
90% on room air.

- Fever (37.5°C) more than 7 days after the onset of fever

- Patients with suspected concomitant bacterial infections (e.g. 1 ng/ml or higher
procalcitonin, etc.) prior to initiation of study drug

- Patients with suspected concomitant fungal infections (e.g. 30 pg/ml or higher
(1-3)-β-d-glucan, etc.) prior to initiation of study drug

- Patients with suspected concurrent congestive heart failure (e.g. 100 pg/mL or higher
NT-pro BNP levels, etc.) prior to initiation of study drug

- Patients with severe hepatic impairment (>Grade 3: ALT >10 times of upper normal
limit)

- Patients with renal impairment requiring dialysis

- Patients with disturbed consciousness such as disturbed orientation

- Pregnant or possibly pregnant patients

- Female patients who are unable to consent to contraceptive use of oral contraceptives,
mechanical contraceptives such as intrauterine devices or barrier devices (pessaries,
condoms), or a combination of these devices during the 7 days after the start of
favipiravir administration.

- Male patients whose partner cannot agree to use the contraception method described in
(10) above

- Patients who cannot consent to the use of condoms from the start of favipiravir
administration to 7 days after the end of favipiravir administration

- Patients with hereditary xanthinuria

- Patients who have previously ever been diagnosed with hypouricemia (< 1 mg/dL) or
xanthine urinary calculi

- Patients with a history of gout or on treatment for gout or hyperuricemia

- Patients receiving immunosuppressants

- Patients who received interferon-alpha or drugs with reported antiviral activity
against SARS-CoV-2 (hydroxychloroquine sulfate, chloroquine phosphate,
lopinavir-ritonavir combination, ciclesonide, nafamostat mesylate, camostat mesylate)
within 9 days after fever (37.5°C or more).

- Patients in whom this episode of infection is a recurrence or reinfection of
SARS-CoV-2 infection

- Patients who have previously received favipiravir (T-705a)

- Other patients judged ineligible by the principal investigator or sub-investigator